Cantor Fitzgerald LP and two affiliate firms escaped claims they unlawfully enforced noncompete provisions in partnership ...
Cantor Fitzgerald raised the firm’s price target on Palvella Therapeutics (PVLA) to $210 from $200 and keeps an Overweight rating on the shares.
Cantor Fitzgerald initiated coverage of DBV Technologies (DBVT) with an Overweight rating and $42 price target DBV Technologies is focused on ...
Detailed price information for Gilead Sciences Inc (GILD-Q) from The Globe and Mail including charting and trades.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback